BACKGROUND: Previously published methods for determination of efavirenz (EFV) in human dried blood spots (DBS) use costly and complex liquid chromatography/mass spectrometry. We describe the validation and evaluation of a simple and inexpensive high-performance liquid chromatography method for EFV quantification in human DBS and dried plasma spots (DPS), using ultraviolet detection appropriate for resource-limited settings. METHODS: One hundred microliters of heparinized whole blood or plasma were spotted onto blood collection cards, dried, punched, and eluted. Eluates are injected onto a C-18 reversed phase high-performance liquid chromatography column. EFV is separated isocratically using a potassium phosphate and acetonitrile mobile phase. Ultraviolet detection is at 245 nm. Quantitation is by use of external calibration standards. Following validation, the method was evaluated using whole blood and plasma from HIV-positive patients undergoing EFV therapy. RESULTS: Mean recovery of drug from DBS is 91.5%. The method is linear over the validated concentration range of 0.3125-20.0 μg/mL. A good correlation (Spearman r = 0.96) between paired plasma and DBS EFV concentrations from the clinical samples was observed, and hematocrit level was not found to be a significant determinant of the EFV DBS level. The mean observed C DBS/C plasma ratio was 0.68. A good correlation (Spearman r = 0.96) between paired plasma and DPS EFV concentrations from the clinical samples was observed. The mean percent deviation of DPS samples from plasma samples is 1.68%. CONCLUSIONS: Dried whole blood spot or dried plasma spot sampling is well suited for monitoring EFV therapy in resource-limited settings, particularly when high sensitivity is not essential.
BACKGROUND: Previously published methods for determination of efavirenz (EFV) in human dried blood spots (DBS) use costly and complex liquid chromatography/mass spectrometry. We describe the validation and evaluation of a simple and inexpensive high-performance liquid chromatography method for EFV quantification in humanDBS and dried plasma spots (DPS), using ultraviolet detection appropriate for resource-limited settings. METHODS: One hundred microliters of heparinized whole blood or plasma were spotted onto blood collection cards, dried, punched, and eluted. Eluates are injected onto a C-18 reversed phase high-performance liquid chromatography column. EFV is separated isocratically using a potassium phosphate and acetonitrile mobile phase. Ultraviolet detection is at 245 nm. Quantitation is by use of external calibration standards. Following validation, the method was evaluated using whole blood and plasma from HIV-positive patients undergoing EFV therapy. RESULTS: Mean recovery of drug from DBS is 91.5%. The method is linear over the validated concentration range of 0.3125-20.0 μg/mL. A good correlation (Spearman r = 0.96) between paired plasma and DBSEFV concentrations from the clinical samples was observed, and hematocrit level was not found to be a significant determinant of the EFVDBS level. The mean observed C DBS/C plasma ratio was 0.68. A good correlation (Spearman r = 0.96) between paired plasma and DPSEFV concentrations from the clinical samples was observed. The mean percent deviation of DPS samples from plasma samples is 1.68%. CONCLUSIONS: Dried whole blood spot or dried plasma spot sampling is well suited for monitoring EFV therapy in resource-limited settings, particularly when high sensitivity is not essential.
Authors: Lisa M Almond; Patrick G Hoggard; Damitha Edirisinghe; Saye H Khoo; David J Back Journal: J Antimicrob Chemother Date: 2005-09-01 Impact factor: 5.790
Authors: R ter Heine; H Rosing; E C M van Gorp; J W Mulder; W A van der Steeg; J H Beijnen; A D R Huitema Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2008-04-08 Impact factor: 3.205
Authors: R Ter Heine; H Rosing; E C M van Gorp; J W Mulder; J H Beijnen; A D R Huitema Journal: J Pharm Biomed Anal Date: 2008-11-05 Impact factor: 3.935
Authors: R Ter Heine; M J X Hillebrand; H Rosing; E C M van Gorp; J W Mulder; J H Beijnen; A D R Huitema Journal: J Pharm Biomed Anal Date: 2008-11-27 Impact factor: 3.935
Authors: Kayla N Ellefsen; Jose Luiz da Costa; Marta Concheiro; Sebastien Anizan; Allan J Barnes; Sandrine Pirard; David A Gorelick; Marilyn A Huestis Journal: Bioanalysis Date: 2015 Impact factor: 2.681